Keyphrases
Core Outcome Set
100%
Clinical Trials
78%
Immune Thrombocytopenic Purpura
66%
Randomized Controlled Trial
38%
Immune Thrombocytopenia
38%
Patient Outcomes
35%
Enzalutamide
33%
Risk Outcomes
33%
Risk-benefit
33%
Patient Benefit
33%
Drug Development
33%
Reporting Guidelines
33%
Trialists
33%
Web-based Survey
33%
Clinical Neurology
33%
Patient Risk
33%
Sectional Analysis
33%
Clinical Trial Registry
31%
Primary ITP
22%
Adverse Events
20%
Health Research
16%
Trial Reporting
14%
Clinical Practice
14%
Data Extraction
12%
Inconsistency
11%
Requirements Selection
11%
Objective Response
11%
Consolidated Standards of Reporting Trials (CONSORT)
11%
Top 100
11%
Primary Immune Thrombocytopenia
10%
Platelet Response
8%
Outcome Reporting
8%
Intervention Effectiveness
8%
International Clinical Trials Registry Platform (ICTRP)
8%
Platelet Count
8%
Search String
8%
Research Quality
7%
Overall Survival
7%
Approved Indication
7%
Histology
7%
Inclusion Criteria
7%
Inferential Statistics
6%
Descriptive Statistics
6%
Everyday Practices
5%
Fashion Data
5%
Platelet Dysfunction
5%
Public Registry
5%
Bleeding Symptoms
5%
Popular
5%
Autoimmune
5%
Medicine and Dentistry
Clinical Trial
75%
Idiopathic Thrombocytopenic Purpura
66%
Randomized Controlled Trial
40%
Clinical Neurology
33%
Cross Sectional Study
33%
Thrombocytopenic Purpura
33%
Platelet
19%
Clinician
13%
Medicine
13%
Adverse Event
9%
Outcome Assessment
9%
Systematic Review
6%
Analysis of Variance
5%
Awareness
5%
Cohort Effect
5%
